pov4-20

ПОВОЛЖСКИЙ
ОНКОЛОГИЧЕСКИЙ
ВЕСТНИК
Gastrointestinal Cancer // The Oncologist. — 2019. —
Vol. 24, №159. — e66.
14. Chakrabarti S., Dong H., Paripat H.R. et al. First Report
of Dramatic Tumor Responses with Ramucirumab
and Paclitaxel After Progression on Pembrolizumab
in Two Cases of Metastatic Gastroesophageal
Adenocarcinoma // The Oncologist. — 2018. —
№23. — Р. 840-843.
15. Gil-Delgadoa M.A., Lucidarmeb O., Ba. Bachet J.
et al. Long-Term Survival in Gastroesophageal
Junction Adenocarcinoma: Ramucirumab // Case Rep
Gastroenterol. — 2018. — №12. — Р. 532-539.
16. Klempner S.J., Maron S.B., Chase L. et al. Initial
Report of Second-Line FOLFIRI in Combination
with Ramucirumab in Advanced Gastroesophageal
Adenocarcinomas: A Multi-Institutional Retrospective
Analysis // The Oncologist. — 2019. — №24. —
Р. 475-482.
17. Tiwari P. Ramucirumab: Boon or bane // Journal of
the Egyptian National Cancer Institute. — 2016. —
№28. — Р. 133-140.
18. Doi Y., Takii Y., Mitsug K. et al. The Effectiveness
of Hepatic Arterial Infusion Chemotherapy with
5-Fluorouracil/Cisplatin and Systemic Chemotherapy
with Ramucirumab in Alpha-Fetoprotein-Producing
Gastric Cancer with Multiple Liver Metastases // Case
Reports in Oncological Medicine. — 2018. — Article
ID 5402313. — 6 p.
19. Arakawa Y., Tamura M., Aiba K. et al. Signifcant
response to ramucirumab monotherapy in
chemotherapy resistant recurrent alpha fetoprotein
producing gastric cancer: A case report // Oncology
letters. — 2017. — №14. — Р. 3039-3042.
20. Matsubara Y., Ando T., Hosokawa A. et al.
Neuroendocrine Carcinoma of the Stomach:
Том 11, №4. 2020
A Response to Combination Chemotherapy
Consisting of Ramucirumab Plus Paclitaxel // Intern
Med. — 2018. — №57. — P. 671-675.
21. Matsumoto H., Kawazoe A., Shimada K. et al.
A retrospective study of the safety and efficacy
of paclitaxel plus ramucirumab in patients with
advanced or recurrent gastric cancer with ascites //
BMC Cancer. — 2018. — Vol. 18, №120.
22. Yoshikawa T., Muro K., Shitara K. et al. Effect of First-line
S-1 Plus Oxaliplatin With or Without Ramucirumab
Followed by Paclitaxel Plus Ramucirumab on
Advanced Gastric Cancer in East Asia The Phase
2 RAINSTORM Randomized Clinical Trial // JAMA
Network Open. — 2019. — Vol. 2, №8. — e198243.
23. Tabernero J., Ohtsu A., Muro K. et al. Exposure-
Response Analyses of Ramucirumab from Two
Randomized, Phase III Trials of Second-line Treatment
for Advanced Gastric or Gastroesophageal Junction
Cancer // Mol Cancer Ther. — 2017. — Vol. 16, №10.
24. Fuchs C.S., Tabernero J., Tomasek J. et al. Biomarker
analyses in REGARD gastric/GEJ carcinoma
patients treated with VEGFR2 targeted antibody
ramucirumab // British Journal of Cancer. — 2016. —
№115. — Р. 974-982.
25. Sorokin M., Poddubskaya E., Baranova M. et al. RNA
sequencing profiles and diagnostic signatures linked
with response to ramucirumab in gastric cancer //
Cold Spring Harb Mol Case Stud. — 2020, February 14.
26. Cutsem E.V., Muro K., Cunningham D. et al. Biomarker
analyses of second-line ramucirumab in patients with
advanced gastric cancer from RAINBOW, aglobal,
randomized, double-blind, phase 3 study // European
Journal of Cancer. — 2020. — №127. — P. 150-157.
62
Обзор литературы